| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Soumita Ghosh, Isabel González-Mariscal, Josephine M Egan, Ruin Moadde. Targeted proteomics of cannabinoid receptor CB1 and the CB1b isoform. Journal of pharmaceutical and biomedical analysis. vol 144. 2018-02-05. PMID:27914737. |
cannabinoid receptors (cbr), including cb1 and cb2 have been therapeutic targets for a number of conditions. |
2018-02-05 |
2023-08-13 |
Not clear |
| Antje Scholl, Igor Ivanov, Burkhard Hin. Inhibition of interleukin-1β-induced endothelial tissue factor expression by the synthetic cannabinoid WIN 55,212-2. Oncotarget. vol 7. issue 38. 2018-01-30. PMID:27556861. |
in addition, the inhibitory effect of win 55,212-2 was not reversed by antagonists to cannabinoid receptors (cb1, cb2) or transient receptor potential vanilloid 1. |
2018-01-30 |
2023-08-13 |
human |
| Helen de Morais, Camila P de Souza, Luisa M da Silva, Daniele M Ferreira, Cristiane Hatsuko Baggio, Ana Carolina Vanvossen, Milene Cristina de Carvalho, José Eduardo da Silva-Santos, Leandro José Bertoglio, Joice M Cunha, Janaina M Zanovel. Anandamide reverses depressive-like behavior, neurochemical abnormalities and oxidative-stress parameters in streptozotocin-diabetic rats: Role of CB1 receptors. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 26. issue 10. 2018-01-29. PMID:27544303. |
for this, diabetic (dbt) male wistar rats were intraperitoneally treated with cannabinoid cb1 (am251, 1mg/kg) or cb2 (am630, 1mg/kg) receptor antagonists followed by anandamide (aea, 0.005mg/kg) and then submitted to the forced swimming test (fst). |
2018-01-29 |
2023-08-13 |
rat |
| Tyler E Gaston, Daniel Friedma. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy & behavior : E&B. vol 70. issue Pt B. 2018-01-16. PMID:28087250. |
it has long been known that ∆9-thc has partial agonist activity at the endocannabinoid receptors cb1 and cb2, though it also binds to other targets which may modulate neuronal excitability and neuroinflammation. |
2018-01-16 |
2023-08-13 |
human |
| Hélène François, Antoine Durrbach, Séverine Beaudreuil, Bernard Charpentier, Lola Lecr. [Role of cannabinoid receptors in renal diseases]. Nephrologie & therapeutique. vol 12 Suppl 1. 2018-01-12. PMID:26968477. |
the cannabinoid system and more specifically the cannabinoid receptors 1 (cb1) and 2 (cb2) may represent a new therapeutic target in chronic kidney disease. |
2018-01-12 |
2023-08-13 |
human |
| Marta Celorrio, Diana Fernández-Suárez, Estefanía Rojo-Bustamante, Víctor Echeverry-Alzate, María J Ramírez, Cecilia J Hillard, José A López-Moreno, Rafael Maldonado, Julen Oyarzábal, Rafael Franco, María S Aymeric. Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease. Brain, behavior, and immunity. vol 57. 2018-01-11. PMID:27318096. |
the symptomatic relief of urb597 was confirmed in haloperidol-induced catalepsy assays, where its anti-cataleptic effects were both blocked by antagonists of the two cannabinoid receptors (cb1 and cb2), and abolished in animals deficient in these receptors. |
2018-01-11 |
2023-08-13 |
mouse |
| Natalia Malek, Magdalena Kostrzewa, Wioletta Makuch, Agnieszka Pajak, Mateusz Kucharczyk, Fabiana Piscitelli, Barbara Przewlocka, Vincenzo Di Marzo, Katarzyna Starowic. The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain. Pharmacological research. vol 111. 2018-01-05. PMID:27326920. |
among the possible targets of these mediators, only the mrna levels of cb2, gpr18 and gpr55, which are believed to be novel cannabinoid receptors, were upregulated in the spinal cord and/or drg of cci rats. |
2018-01-05 |
2023-08-13 |
rat |
| Elk Kossatz, Rafael Maldonado, Patricia Robled. CB2 cannabinoid receptors modulate HIF-1α and TIM-3 expression in a hypoxia-ischemia mouse model. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 26. issue 12. 2018-01-05. PMID:28253997. |
cb2 cannabinoid receptors modulate hif-1α and tim-3 expression in a hypoxia-ischemia mouse model. |
2018-01-05 |
2023-08-13 |
mouse |
| Elk Kossatz, Rafael Maldonado, Patricia Robled. CB2 cannabinoid receptors modulate HIF-1α and TIM-3 expression in a hypoxia-ischemia mouse model. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 26. issue 12. 2018-01-05. PMID:28253997. |
the role of cb2 cannabinoid receptors (cb |
2018-01-05 |
2023-08-13 |
mouse |
| Cristiane R de Carvalho, Alexandre A Hoeller, Pedro L C Franco, Athos P S Martini, Flávia M S Soares, Katia Lin, Rui D Prediger, Benjamin J Whalley, Roger Wal. The cannabinoid CB2 receptor-specific agonist AM1241 increases pentylenetetrazole-induced seizure severity in Wistar rats. Epilepsy research. vol 127. 2018-01-02. PMID:27608434. |
the cannabinoid cb2 receptor-specific agonist am1241 increases pentylenetetrazole-induced seizure severity in wistar rats. |
2018-01-02 |
2023-08-13 |
rat |
| Fang Gao, Ling-Hong Zhang, Tang-Feng Su, Lin Li, Rui Zhou, Miao Peng, Cai-Hua Wu, Xiao-Cui Yuan, Ning Sun, Xian-Fang Meng, Bo Tian, Jing Shi, Hui-Lin Pan, Man L. Signaling Mechanism of Cannabinoid Receptor-2 Activation-Induced β-Endorphin Release. Molecular neurobiology. vol 53. issue 6. 2017-12-29. PMID:26108183. |
activation of cannabinoid receptor-2 (cb2) results in β-endorphin release from keratinocytes, which then acts on primary afferent neurons to inhibit nociception. |
2017-12-29 |
2023-08-13 |
rat |
| Renata Androvicova, Jiri Horacek, Tibor Stark, Filippo Drago, Vincenzo Mical. Endocannabinoid system in sexual motivational processes: Is it a novel therapeutic horizon? Pharmacological research. vol 115. 2017-12-27. PMID:27884725. |
the endocannabinoid system (ecs), which is composed of the cannabinoid receptors types 1 and 2 (cb1 and cb2) for marijuana's psychoactive ingredient Δ |
2017-12-27 |
2023-08-13 |
Not clear |
| Cristina Palomo-Garo, Yolanda Gómez-Gálvez, Concepción García, Javier Fernández-Rui. Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice. Pharmacological research. vol 110. 2017-12-21. PMID:27063942. |
targeting the cannabinoid cb2 receptor to attenuate the progression of motor deficits in lrrk2-transgenic mice. |
2017-12-21 |
2023-08-13 |
mouse |
| Cristina Palomo-Garo, Yolanda Gómez-Gálvez, Concepción García, Javier Fernández-Rui. Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice. Pharmacological research. vol 110. 2017-12-21. PMID:27063942. |
we designed a long-term study with these animals aimed at: (i) elucidating the changes experienced by the endocannabinoid signaling system in the basal ganglia during the progression of the disease in these mice, paying emphasis in the cb2 receptor, which has emerged as a promising target in pd, and (ii) evaluating the potential of compounds selectively activating this cb2 receptor, as disease-modifying agents in these mice. |
2017-12-21 |
2023-08-13 |
mouse |
| Cristina Palomo-Garo, Yolanda Gómez-Gálvez, Concepción García, Javier Fernández-Rui. Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice. Pharmacological research. vol 110. 2017-12-21. PMID:27063942. |
furthermore, there were no changes in the status of the cb2 receptor, as well as in other elements of the endocannabinoid signaling, in the basal ganglia, but, paradoxically, the selective activation of this receptor partially reversed the deficits in the hanging-wire test of lrrk2 transgenic mice. |
2017-12-21 |
2023-08-13 |
mouse |
| Natalia Murataeva, Amey Dhopeshwarkar, Danielle Yin, José Mitjavila, Heather Bradshaw, Alex Straiker, Ken Macki. Where's my entourage? The curious case of 2-oleoylglycerol, 2-linolenoylglycerol, and 2-palmitoylglycerol. Pharmacological research. vol 110. 2017-12-21. PMID:27117667. |
2-arachidonoylglycerol (2-ag) is the most abundant endogenous cannabinoid in the brain and an agonist at two cannabinoid receptors (cb1 and cb2). |
2017-12-21 |
2023-08-13 |
Not clear |
| Tiziana Bisogno, Sergio Oddi, Alessandra Piccoli, Domenico Fazio, Mauro Maccarron. Type-2 cannabinoid receptors in neurodegeneration. Pharmacological research. vol 111. 2017-12-19. PMID:27450295. |
based on its wide expression in immune cells, type-2 cannabinoid (cb2) receptors were traditionally thought to act as "peripheral receptors" with an almost exclusively immunomodulatory function. |
2017-12-19 |
2023-08-13 |
Not clear |
| Sevil Köse, Fatima Aerts-Kaya, Çağla Zübeyde Köprü, Emirhan Nemutlu, Barış Kuşkonmaz, Beren Karaosmanoğlu, Ekim Zihni Taşkıran, Belgin Altun, Duygu Uçkan Çetinkaya, Petek Korkusu. Human bone marrow mesenchymal stem cells secrete endocannabinoids that stimulate in vitro hematopoietic stem cell migration effectively comparable to beta-adrenergic stimulation. Experimental hematology. vol 57. 2017-12-19. PMID:29030083. |
endocannabinoids (ecbs) are endogenous lipid mediators generated in the brain and peripheral tissues and activate the cannabinoid receptors cb1 and cb2. |
2017-12-19 |
2023-08-13 |
human |
| Mariana M Almeida, Camilla P Dias-Rocha, André S Souza, Mariana F Muros, Leonardo S Mendonca, Carmen C Pazos-Moura, Isis H Trevenzol. Perinatal maternal high-fat diet induces early obesity and sex-specific alterations of the endocannabinoid system in white and brown adipose tissue of weanling rat offspring. The British journal of nutrition. vol 118. issue 10. 2017-12-13. PMID:29110748. |
the ecs consists of endocannabinoids, cannabinoid receptors (cannabinoid type-1 receptor (cb1) and cannabinoid type-2 receptor (cb2)) and metabolising enzymes. |
2017-12-13 |
2023-08-13 |
human |
| Maria Grazia Cascio, Pietro Marini, Roger G Pertwe. The Displacement Binding Assay Using Human Cannabinoid CB2 Receptor-Transfected Cells. Methods in molecular biology (Clifton, N.J.). vol 1412. 2017-12-07. PMID:27245891. |
the displacement binding assay using human cannabinoid cb2 receptor-transfected cells. |
2017-12-07 |
2023-08-13 |
human |